Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
PHAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.07 - $19.71
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.20M
Market Cap
$459.60M
Enterprise Value$1.35B
Total Cash (Recent Filing)$297.26M
Total Debt (Recent Filing)$201.91M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 13, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.35
Shares Outstanding69,636,970
10 Day Avg. Volume1,284,300
30 Day Avg. Volume1,198,648
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.85
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.61
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$21.13Price Target Upside220.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVoquezna revenue reported at $29.7M was well above the FactSet consensus of $24.9M.
Market InterestShares are up 35% in recent sessions, suggesting real incremental interest or potentially emerging broader corporate activity like mergers or acquisitions.
Product GrowthOver 300,000 filled prescriptions for VOQUEZNA demonstrate strong market penetration and growth potential.
Bears Say
FDA Process ConcernsThe issue with the FDA process is expected to continue being an overhang, putting pressure on PHAT shares.
Patent UncertaintyThere is elevated uncertainty due to the company's unsuccessful efforts to extend exclusivity to 2032, resulting in a forecasted loss of exclusivity in 2030.
Seasonal TrendsFirst quarter trends are softer than expected, affected by typical seasonality factors such as holiday impact, a shortened month, and deductible resets.
---
Ownership Overview
18.29% Insiders
15.59% Mutual Funds
0.11% Other Institutional Investors
57.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $4.07 and its highest was $19.71 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $459.60M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 42 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.165.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -1.11.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 69,636,970 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went down -2.961%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Currently, no hedge funds are holding shares in PHAT
---
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.13 (220.15% Upside)
$21.13 (220.15% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.85%
12-Months-Change
Fundamentals
Return on Equity
181.41%
Trailing 12-Months
Asset Growth
-8.55%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
---
PHAT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong prescription growth, market positioning, and revenue performance for VOQUEZNA, but also addressed challenges such as potential legal issues with the FDA and anticipated Q1 revenue softness.Read More>---
PHAT Stock 12 Month Forecast
Average Price Target
$21.13
▲(220.15% Upside)
Technical Analysis
Ironwood Pharma
―
Supernus Pharmaceuticals
―
Vertex Pharmaceuticals
―
AbbVie
―
RedHill Biopharma
―
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+7.26%
reiterated a buy rating 25 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +7.26% per trade.
---